BHCN Stock Chart & Stats
$83.00
$0.00(0.00%)
At close: 4:00 PM EDT
$83.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$83.00 - $152.00
Previous CloseN/A
Volume0.00
Average Volume (3M)353.00
Market Cap
$44.66B
Enterprise Value$30.89K
Total Cash (Recent Filing)$1.30B
Total Debt (Recent Filing)$20.80B
Price to Earnings (P/E)―
Beta-0.23
Next Earnings
Oct 29, 2026EPS Estimate
21.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.21
Shares Outstanding373,990,570
10 Day Avg. Volume460
30 Day Avg. Volume353
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-4.65
Price to Sales (P/S)0.25
P/FCF Ratio2.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$138.78Price Target Upside67.21% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)73.73
Revenue Forecast (FY)$183.56B
Bulls Say, Bears Say
Bulls Say
Recurring Strong Cash GenerationConsistent, sizable operating cash flow and recurring free cash flow strengthen the firm's ability to service and reduce debt, fund R&D or capex, and absorb shocks. Over the medium term this improves financial flexibility relative to earnings volatility and supports deleveraging efforts.
Sustained Revenue And Margin ExpansionA multi-quarter track record of top-line growth and expanding adjusted margins indicates durable demand, pricing power, and operating leverage. This trend underpins sustained profitability potential and improves predictability of core cash generation over the next several quarters.
Diversified Product Franchises And Geographic GrowthRevenue coming from multiple therapeutic franchises (gastro, dermatology, eye health) and accelerating international and Solta contributions reduces reliance on any single product or market. This structural diversification supports steadier revenue and offsets isolated LOE or regional headwinds.
Bears Say
Very High Leverage And Negative EquityPersistent debt levels near $20B–$22B and a recurring equity deficit materially weaken financial flexibility. High leverage raises refinancing and covenant risk, increases sensitivity to cash-flow shocks, and constrains strategic investments or M&A over the medium term.
Dependence On Xifaxan Exclusivity/IP OutcomeA material portion of forward EBITDA assumes continued Xifaxan exclusivity; an adverse IP outcome would cause a rapid, structural revenue and EBITDA decline. That creates cliff risk for long-term cash flow and complicates capital allocation and deleveraging plans.
Structural Policy And Product-LOE HeadwindsOngoing gross-to-net changes, loss of exclusivity impacts, and Medicaid/340B erosions are persistent revenue and margin pressures. Coupled with potential policy changes (rebates/tariffs), these reduce forecastability of earnings and can materially compress margins over 2–6 months and beyond.
Bausch Health Companies News
BHCN FAQ
What was Bausch Health Companies’s price range in the past 12 months?
Bausch Health Companies lowest stock price was $83.00 and its highest was $152.00 in the past 12 months.
What is Bausch Health Companies’s market cap?
Bausch Health Companies’s market cap is $44.66B.
When is Bausch Health Companies’s upcoming earnings report date?
Bausch Health Companies’s upcoming earnings report date is Oct 29, 2026 which is in 87 days.
How were Bausch Health Companies’s earnings last quarter?
Bausch Health Companies released its earnings results on Jul 29, 2026. The company reported $21.852 earnings per share for the quarter, beating the consensus estimate of $17.249 by $4.603.
Is Bausch Health Companies overvalued?
According to Wall Street analysts Bausch Health Companies’s price is currently Undervalued.
Does Bausch Health Companies pay dividends?
Bausch Health Companies does not currently pay dividends.
What is Bausch Health Companies’s EPS estimate?
Bausch Health Companies’s EPS estimate is 21.16.
How many shares outstanding does Bausch Health Companies have?
Bausch Health Companies has 373,990,570 shares outstanding.
What happened to Bausch Health Companies’s price movement after its last earnings report?
Bausch Health Companies reported an EPS of $21.852 in its last earnings report, beating expectations of $17.249. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Bausch Health Companies?
Currently, no hedge funds are holding shares in MX:BHCN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bausch Health Companies Stock Smart Score
Company Description
Bausch Health Companies
Bausch Health Companies Inc. is a global healthcare enterprise dedicated to the creation, production, and sale of a diverse array of pharmaceutical, medical device, and over-the-counter items. Its primary therapeutic focus areas include eye health, digestive system issues, and dermatological conditions. The company's operations are strategically organized into five key divisions: Bausch + Lomb, which specializes in vision care, surgical solutions, and ophthalmic pharmaceuticals; Salix, concentrating on gastroenterology products within the United States; International Rx, offering a broad portfolio encompassing Solta products, branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across numerous international markets in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East; Ortho Dermatologics, providing dermatological products in the U.S. and Solta medical aesthetic devices globally; and Diversified Products, covering pharmaceutical products in neurology and other therapeutic classes, alongside generic and dentistry items in the United States. Previously known as Valeant Pharmaceuticals International, Inc., the company adopted its current name in July 2018 and maintains its headquarters in Laval, Canada.
BHCN Company Deck
BHCN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum with multiple quarters of consistent top-line and margin expansion, exceptional cash generation, meaningful net-debt reduction, and raised full-year guidance. Management flagged identifiable second-half headwinds (gross-to-net accruals, Aplenzin LOE, gradual Medicaid/340B erosion) and longer-term uncertainties (Xifaxan IP outcome, policy risks), but characterized many drivers of outperformance as transitional. Overall, the positive growth, margin improvement, cash flow strength, and upgraded guidance outweigh the listed challenges.View all MX:BHCN earnings summariesBHCN Revenue Breakdown
47.34% Bausch + Lomb
25.69% Salix
12.23% International
10.77% Diversified Products
3.96% Solta Medical
BHCN Stock 12 Month Forecast
Average Price Target
$138.78
▲(67.21% Upside)